Generate Biomedicines, Inc.
Research Generate Biomedicines, Inc. (GENB) on Bullrun: market cap USD 1.78B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGENB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.78B
- Financial periodQ2 2026
- RevenueUSD 6.31M
- Net income-USD 67.26M
- Free cash flow-USD 58.88M
Valuation Snapshot
latest market cap is USD 1.78B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 31.89M | -USD 203.15M | -USD 204.13M | n/a | -2.18 | USD 121.65M | USD 68.53M | -USD 615.97M |
| FY2024 | USD 20.46M | -USD 173.77M | -USD 121.20M | n/a | -2.09 | USD 176.27M | USD 76.97M | -USD 434.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 1.78B | n/a | n/a | n/a |
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Generate Biomedicines, Inc.'s market cap?
Generate Biomedicines, Inc.'s market capitalization is USD 1.78B.
What does Generate Biomedicines, Inc. do?
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy.